cbdMD (YCBD) Net Margin (2016 - 2026)

cbdMD (YCBD) posted Net Margin of 6.47% for Q4 2025, up 55.08% sequentially from 14.4% in Q3 2025, and up 1280.0% YoY from 0.47% in Q4 2024.

cbdMD (YCBD) Net Margin (2016 - 2026) Analysis & Trends

cbdMD has reported Net Margin for 10 years, with the latest figure at 6.47% in Q4 2025.

Quarterly Net Margin rose 1280.0% year-over-year to 6.47% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 19.45% (up 1459.0% YoY) and the FY2025 annual result came in at 22.8%, up 1587.0% from the prior year.
Net Margin climbed to 6.47% in Q4 2025 per YCBD's latest filing, from 14.4% in the prior quarter.
Over five years, Net Margin peaked at 8.61% in Q2 2021 and troughed at 379.79% in Q2 2022.
A 5-year average of 85.69% and a median of 39.71% in 2021 frame the typical range for Net Margin.
The sharpest annual moves came in 2022 and 2023: Net Margin slumped 38839 bps in 2022, then jumped 33451 bps in 2023.
Over 5 years, Net Margin stood at 204.54% in 2021, then soared by 61 bps to 79.43% in 2022, then surged by 53 bps to 37.15% in 2023, then surged by 48 bps to 19.27% in 2024, then jumped by 66 bps to 6.47% in 2025.
According to Business Quant data, Net Margin over the past three periods registered 6.47%, 14.4%, and 26.67% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-13.91%
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	9.28%
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	42.51%
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	-3.16%
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	15.06%
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	3.95%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	cbdMD	5.41 Mn	3.29 Mn	3.04 Mn	-21.58%

Download Data